CN100427080C - 含有薁磺酸钠的灌肠剂 - Google Patents
含有薁磺酸钠的灌肠剂 Download PDFInfo
- Publication number
- CN100427080C CN100427080C CNB2006100141626A CN200610014162A CN100427080C CN 100427080 C CN100427080 C CN 100427080C CN B2006100141626 A CNB2006100141626 A CN B2006100141626A CN 200610014162 A CN200610014162 A CN 200610014162A CN 100427080 C CN100427080 C CN 100427080C
- Authority
- CN
- China
- Prior art keywords
- enema
- sodium
- water
- sodium azulene
- azulene sulfonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 title claims abstract description 29
- 239000007920 enema Substances 0.000 title claims abstract description 25
- 241000792859 Enema Species 0.000 claims abstract description 24
- 229940095399 enema Drugs 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 14
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims abstract description 11
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims abstract description 9
- 229960001940 sulfasalazine Drugs 0.000 claims abstract description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 8
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 7
- 239000008213 purified water Substances 0.000 claims abstract description 6
- 239000008227 sterile water for injection Substances 0.000 claims abstract description 5
- 239000008215 water for injection Substances 0.000 claims abstract description 5
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 7
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 abstract description 12
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 10
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000035699 permeability Effects 0.000 abstract description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 2
- 229940068968 polysorbate 80 Drugs 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 239000008589 Cortex Fraxini Substances 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 229920001875 Ebonite Polymers 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036783 Proctitis ulcerative Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000009806 pulsatillae Substances 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Abstract
本发明公开一种含有薁磺酸钠的灌肠剂，每50ml～100ml灌肠剂中含有：薁磺酸钠6～12mg；柳氮磺胺吡啶1～2g；氢化可的松30～50mg；混悬剂3～4g，用水补至全量。所述的混悬剂为：吐温-80和胆酸钠。所述的吐温-80和胆酸钠的用量比为1∶1。所述的水选用纯化水、注射用水、灭菌注射用水中的一种。本发明含有薁磺酸钠的灌肠剂，用于治疗溃疡性结肠炎，可以使药物直达局部病灶处，有利于局部肠道组织对药物的吸收，增强通透性，达到治疗的目的。特别是薁磺酸钠与柳氮磺胺吡啶合用，可以发挥各自的优势，达到最佳的治疗效果。而且，本含有薁磺酸钠的灌肠剂，使用简单，不受任何条件的限制，根据医嘱及说明书即可使用。
Description
技术领域
本发明涉及一种灌肠剂。特别是涉及一种用于治疗溃疡性结肠炎，可减轻直肠出血、发热、腹痛、腹泻等症状的含有薁磺酸钠的灌肠剂。
背景技术
溃疡性结肠炎是一种发生于结肠粘膜的慢性、炎症性及溃疡性疾病，最典型的特征是血性腹泻。溃疡性结肠炎的病因是由于遗传因素导致机体对环境、饮食或感染因子等产生不能调节的肠道免疫反应。
溃疡性结肠炎，常自乙状结肠开始，逐渐蔓延至整个结肠。患者有左下腹痛，腹泻，每天大便次数可达十余次以上，便中含有粘液和浓血，有时出血显著。
对于溃疡性结肠炎，一般均采用综合疗法。其中，柳氮磺胺吡啶、各种抗菌药(如四环素、灭滴灵)、类固醇和对症治疗药物(如轻微抗症药、镇静剂)、中药灌肠剂等是常用的药物。而在免疫抑制剂中如：6-巯基嘌呤、硫唑嘌呤、环孢菌素等，必须慎用，且只限极为特殊情况时用。
据研究，薁磺酸钠对人体消化系统、呼吸系统、泌尿系统、皮肤及结膜等部位发生的各种炎症、溃疡和烫伤等均有良好的疗效。如日本生产的麦滋林颗粒销售居世界首位，它与H2受体抑制剂合用，相辅相成，可达到治疗慢性胃炎和消化道溃疡的最佳效果。
发明内容
本发明所要解决的技术问题是，提供一种用于治疗溃疡性结肠炎，可减轻直肠出血、发热、腹痛、腹泻等症状的含有薁磺酸钠的灌肠剂。
本发明所采用的技术方案是：一种含有薁磺酸钠的灌肠剂，每50ml～100ml灌肠剂量中含有：薁磺酸钠6～12mg；柳氮磺胺吡啶1～2g；氢化可的松30～50mg；混悬剂3～4g，用水补至全量。所述的混悬剂为：吐温-80和胆酸钠。所述的吐温-80和胆酸钠的用量比为1∶1。所述的水选用纯化水、注射用水、灭菌注射用水中的一种。
本发明的含有薁磺酸钠的灌肠剂，用于治疗溃疡性结肠炎，可以使药物直达局部病灶处，有利于局部肠道组织对药物的吸收，增强通透性，达到治疗的目的。特别是薁磺酸钠与柳氮磺胺吡啶合用，可以发挥各自的优势，达到最佳的治疗效果。而且，本含有薁磺酸钠的灌肠剂，使用操作简单，不受任何条件的限制，根据医嘱及说明书即可使用。
具体实施方式
下面结合实施例对本发明的含有薁磺酸钠的灌肠剂做出详细说明。
本发明的含有薁磺酸钠的灌肠剂，每配制50ml～100ml灌肠剂量中含有：薁磺酸钠6～12mg；柳氮磺胺吡啶1～2g；氢化可的松30～60mg；混悬剂3～3.5g，用水补至全量。
其中，所述的混悬剂为：吐温-80和胆酸钠，其吐温-80和胆酸钠的用量比为1∶1；所述的水选用纯化水、注射用水、灭菌注射用水中的一种。
作为本发明的有效成分薁磺酸钠，化学名称为1.4-二甲基-7-异丙基-3-薁磺酸钠，化学通式为：C15H17NaO3S·1/2H2O，结构式为：
对人体消化系统、呼吸系统、泌尿系统、皮肤及结膜等部位发生的各种炎症、溃疡和烫伤等均有良好的疗效。
柳氮磺胺吡啶，分子式为C18H14O5N4S。为一种肠道磺胺药。本品对结缔组织有特殊的亲和力。口服后自肠道中吸收较少，被肠道结缔组织所分解，并释出磺胺吡啶起治疗作用。临床主要用于慢性溃疡性直肠炎和结肠炎。因此，薁磺酸钠与柳氮磺胺吡啶合用，可以发挥各自的优势，达到最佳的治疗效果。
实施例1：
在带有搅拌器的混合器中，首先加入10升灭菌注射用水，加温到60℃，搅拌下，加入吐温-801.5千克、胆酸钠1.5千克，搅拌15分钟，再依次加入薁磺酸钠6克、柳氮磺胺吡啶2千克、氢化可的松30克，搅拌30分钟，加灭菌注射用水至50升，再搅拌15分钟。过滤后，用自动分装机分装，每小袋50毫升，共1000袋。
实施例2：
在带有搅拌器的混合器中，首先加入10升注射用水，加温到60℃，搅拌下，加入吐温-801.75千克、胆酸钠1.75千克，搅拌15分钟，再依次加入薁磺酸钠9克、柳氮磺胺吡啶2千克、氢化可的松50克，搅拌30分钟，加注射用水至75升，再搅拌15分钟。过滤后，用自动分装机分装，每小袋75毫升，共1000袋。
实施例3：
在带有搅拌器的混合器中，首先加入10升纯化水，加温到60℃，搅拌下，加入吐温-801.75千克、胆酸钠1.75千克，搅拌15分钟，再依次加入薁磺酸钠12克、柳氮磺胺吡啶2千克、氢化可的松60克，搅拌30分钟，加纯化水至100升，再搅拌15分钟。过滤后，用自动分装机分装，每小袋100毫升，共1000袋。
使用灌肠剂一般在晚睡前，首先用温水清洗肛门周围，然后让患者取胸膝位，并在肛门外涂润滑油少许，用硬胶管在充分润滑下缓慢插入直肠，插管的深度应根据病变部位而定，一般在15～25cm。将留在体外的胶管另一端连接在盛有50毫升本发明的灌肠剂药液的注肛器上，再将药液缓慢注入到肠腔内充分扩散，然后改成侧卧即可。灌肠后应卧床休息10分钟左右，并在较长时间后(2小时以上)再解大便，这样极有利于药物的吸收发挥作用。
本含有薁磺酸钠的灌肠剂，使用次数为每日一次为宜，这样不仅可以减少对肠道的刺激，还可保证让药物吸收的连续性。
临床疗效实验：
选62例轻至中度溃疡性结肠炎患者，进行疗效观察，其年龄在25～61之间，平均年龄42.5岁。患者临床表现为腹痛、腹泻、大便粘滞或带脓血、脘腹痞闷、纳少乏力等。接受灌肠治疗，每天进行一次，采用100毫升灌肠剂治疗量，用药量与年龄无关，一周后，改为隔日一次，维持2周，于2周后逐渐停止，其间用药为每3天治疗一次，共治疗4次。
实验结果：55人有效或好转，有效率为88％；无效10人，占总人数的16％。
另选36例轻至中度溃疡性结肠炎患者，年龄在25～60之间，平均年龄44岁。采用市面上出售的一种中药(处方为：白头翁10克、黄柏10克、黄连10克、秦皮10克、青袋5克、人工牛黄5克的煎液100毫升)，进行灌肠治疗，每天进行1次，1周后，改为隔日1次，维持2周，2周后逐渐停药，其间用药改为每3天治疗1次，共治疗4次。
结果：其中28人有效或好转，有效率为77.8％，无效8人，占22.2％。
相比采用薁磺酸钠的灌肠剂进行治疗，疗效显著，且无副作用。
Claims (3)
1.一种含有薁磺酸钠的灌肠剂，其特征在于，每50ml～100ml灌肠剂量中含有：薁磺酸钠6～12mg；柳氮磺胺吡啶1～2g；氢化可的松30～60mg；由吐温-80和胆酸钠组成的混悬剂3～3.5g，用水补至全量。
2.根据权利要求1所述的含有薁磺酸钠的灌肠剂，其特征在于，所述的吐温-80和胆酸钠的用量比为1∶1。
3.根据权利要求1所述的含有薁磺酸钠的灌肠剂，其特征在于，所述的水选用纯化水、注射用水、灭菌注射用水中的一种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100141626A CN100427080C (zh) | 2006-06-08 | 2006-06-08 | 含有薁磺酸钠的灌肠剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100141626A CN100427080C (zh) | 2006-06-08 | 2006-06-08 | 含有薁磺酸钠的灌肠剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1861046A CN1861046A (zh) | 2006-11-15 |
| CN100427080C true CN100427080C (zh) | 2008-10-22 |
Family
ID=37388632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100141626A Active CN100427080C (zh) | 2006-06-08 | 2006-06-08 | 含有薁磺酸钠的灌肠剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100427080C (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379820B (zh) * | 2011-08-31 | 2013-09-18 | 天津市顶硕科贸有限公司 | 薁磺酸钠水溶液 |
| CN105213487A (zh) * | 2015-10-16 | 2016-01-06 | 天津市顶硕科贸有限公司 | 一种治疗溃疡性直肠炎的灌肠剂及其制备方法 |
| CN107519493A (zh) * | 2016-06-20 | 2017-12-29 | 天津金耀集团有限公司 | 含有薁磺酸盐的皮肤药物组合物 |
| CN107519182A (zh) * | 2016-06-20 | 2017-12-29 | 天津金耀集团有限公司 | 以丁酸氢化可的松为活性成分的皮肤药物组合物 |
| CN111973636A (zh) * | 2019-05-21 | 2020-11-24 | 王飞 | 一种肛肠凝胶及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1561986A (zh) * | 2004-04-11 | 2005-01-12 | 张红军 | 含有l－谷氨酰胺和薁磺酸钠的胶囊剂 |
-
2006
- 2006-06-08 CN CNB2006100141626A patent/CN100427080C/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1561986A (zh) * | 2004-04-11 | 2005-01-12 | 张红军 | 含有l－谷氨酰胺和薁磺酸钠的胶囊剂 |
Non-Patent Citations (6)
| Title |
|---|
| 新型胃炎及溃疡治疗剂—麦滋林-S. 查仲玲.医药导报.新药与临床，第10卷第5期. 1991 |
| 新型胃炎及溃疡治疗剂—麦滋林-S. 查仲玲.医药导报.新药与临床，第10卷第5期. 1991 * |
| 麦滋林-S、替硝唑、柳氮磺胺吡啶保留灌肠治疗溃疡性结肠炎. 谭立群.实用医学杂志，第18卷第6期. 2002 |
| 麦滋林-S、替硝唑、柳氮磺胺吡啶保留灌肠治疗溃疡性结肠炎. 谭立群.实用医学杂志，第18卷第6期. 2002 * |
| 麦滋林灌肠治疗溃疡性结肠炎的疗效观察. 曾仕平等.中国热带医学，第6卷第4期. 2006 |
| 麦滋林灌肠治疗溃疡性结肠炎的疗效观察. 曾仕平等.中国热带医学，第6卷第4期. 2006 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1861046A (zh) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100427080C (zh) | 含有薁磺酸钠的灌肠剂 | |
| CN106729212A (zh) | 治疗痛风急性期的复方中药组合物及其应用 | |
| CN101327225A (zh) | 一种蜂蜜酸合剂和制备方法及其应用 | |
| CN104069441A (zh) | 一种治疗泌尿系统结石的中药组合物 | |
| CN103585585A (zh) | 一种治疗胆总管结石的中药组合物及其制备方法 | |
| CN101023988B (zh) | 治疗小儿腹泻的中药制剂 | |
| CN105726634A (zh) | 一种治疗鼻炎病的中药制剂 | |
| CN101229238B (zh) | 治疗前列腺疾病的中药制剂 | |
| CN1259079C (zh) | 治疗骨病的膏药 | |
| CN109966442A (zh) | 一种治疗溃疡性结肠炎的内服外用中药组合物及其制备方法 | |
| CN104127668A (zh) | 一种治疗慢性咽炎的中药制剂 | |
| CN103720949A (zh) | 通便肠清胶囊及制备方法 | |
| Daniels et al. | Giving laxatives safely and effectively | |
| CN1140287C (zh) | 治疗脾胃疾病的口服药物 | |
| CN106266405A (zh) | 一种治疗胃胀的药物 | |
| CN107243038A (zh) | 一种治疗痛风的药物组合物 | |
| CN1088378C (zh) | 治疗慢性浅表性胃炎的中药口服液及其制备方法 | |
| RU2150277C1 (ru) | Лечение констипации методом кишечного лаважа в.а.маткевича | |
| Latif | Huqna (Enema & Basti) Therapy | |
| CN106728620B (zh) | 一种用于改善肿瘤化疗患者便秘的通便合剂 | |
| Dedge et al. | Scope of Ayurveda Interventions to Improve Palliative Care Practices in Terminally Ill Cancer Patients | |
| CN104127814A (zh) | 一种治疗盆腔炎的中药制剂 | |
| US20100055204A1 (en) | Use of hydrochloric acid in the manufacture of medicament for treating disease caused by fouling of transport tract | |
| Wang et al. | An Exploration of Dr. Chunying Liu's Experience in Treating Frequent Nephrotic Syndrome in Children | |
| RU2177790C2 (ru) | Способ лечения больных язвенной болезнью двенадцатиперстной кишки |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Enteroclysis contg. sodium azulene-sulfonate Effective date of registration: 20131012 Granted publication date: 20081022 Pledgee: Bank of Tianjin Limited by Share Ltd science and Technology Branch Pledgor: Tianjin Jing Shuo Science and Trade Co., Ltd. Registration number: 2013120000042 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20140928 Granted publication date: 20081022 Pledgee: Bank of Tianjin Limited by Share Ltd science and Technology Branch Pledgor: Tianjin Jing Shuo Science and Trade Co., Ltd. Registration number: 2013120000042 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160219 Address after: 300308, B205, building 8, airport business park, 80 Ring Road North, Tianjin Airport Economic Zone Patentee after: Tianjin top pharmaceutical technology Co., Ltd. Address before: 300110 Tianjin city Xiqing District Zhangjiawo Industrial Zone Fengze Road No. 6 Patentee before: Tianjin Jing Shuo Science and Trade Co., Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 300308, Tianjin free trade test area (Airport Economic Zone), No. 80 North River Road Airport Business Park East 8 building, B205 Patentee after: Tianjin top pharmaceutical Limited by Share Ltd Address before: 300308, B205, building 8, airport business park, 80 Ring Road North, Tianjin Airport Economic Zone Patentee before: Tianjin top pharmaceutical technology Co., Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Enema containing sodium azulenesulfonate Effective date of registration: 20210318 Granted publication date: 20081022 Pledgee: Business Department of Bank of Tianjin Co.,Ltd. Pledgor: Tianjin top pharmaceutical Limited by Share Ltd. Registration number: Y2021120000008 |